Catalogue Number
BN-O1500
Analysis Method
HPLC,NMR,MS
Specification
98%(HPLC)
Storage
-20℃
Molecular Weight
584.7
Appearance
Powder
Botanical Source
This product is isolated and purified from the seeds of Melia toosendan Sieb. et Zucc.
Structure Type
Triterpenoids
Category
Standards;Natural Pytochemical;API
SMILES
CC=C(C)C(=O)OC1C2C3C(CO2)(C(CC(C3(C4C1(C5=C(C(CC5OC(C4)O)C6=COC=C6)C)C)C)O)OC(=O)C)C
Synonyms
2-Butenoic acid, 2-methyl-, (2R,3aS,5R,6aR,6bR,7S,9R,9aR,11aR,11bR,12S,12aR)-9-(acetyloxy)-2-(3-furanyl)-3,3a,6,6a,6b,7,8,9,9a,10,11a,11b,12,12a-tetradecahydro-5,7-dihydroxy-1,6b,9a,12a-tetramethyl-2H,5H-cyclopenta[b]furo[2',3',4':4,5]naphth[2,1-d]oxepin-12-yl ester, (2E)-/(2R,3aS,5R,6aR,6bR,6b1R,7S,9R,9aR,11aR,12S,12aR)-9-acetoxy-2-(furan-3-yl)-5,7-dihydroxy-1,6b,9a,12a-tetramethyl-3,3a,6,6a,6b,6b1,7,8,9,9a,10,11a,12,12a-tetradecahydro-2H,5H-cyclopenta[b]furo[2',3',4':4,5]naphtho[2,1-d]oxepin-12-yl (E)-2-methylbut-2-enoate/(2R,3aS,5R,6aR,6bR,7S,9R,9aR,11aR,11bR,12S,12aR)-9-Acetoxy-2-(3-furyl)-5,7-dihydroxy-1,6b,9a,12a-tetramethyl-3,3a,6,6a,6b,7,8,9,9a,10,11a,11b,12,12a-tetradecahydro-2H,5H-cyclopenta[b]furo[2',3',4':4,5]naphtho[2,1-d]oxepin-12-yl (2E)-2-methyl-2-butenoate
IUPAC Name
[(1R,2R,4R,6S,8R,11R,12S,13R,16R,17R,19S,20R)-17-acetyloxy-8-(furan-3-yl)-4,19-dihydroxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.02,11.06,10.016,20]icos-9-en-12-yl] (E)-2-methylbut-2-enoate
Density
1.3±0.1 g/cm3
Solubility
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Flash Point
356.2±31.5 °C
Boiling Point
665.4±55.0 °C at 760 mmHg
Melting Point
InChl
InChl Key
YOBMBNWOJMLHDF-VOYNGPTCSA-N
WGK Germany
RID/ADR
HS Code Reference
2933990000
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:76689-98-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
24899848
A review of the microgastropod genus Systenostoma is provided. Thai and Malaysian species are transferred to a new genus, Angustopila (type species: Systenostoma tamlod Panha & Burch, 1999). A new subterranean Angustopila species is described here. Conchologically, the new species is most similar to the cave-dwelling, Thai A. tamlod (Panha & Burch, 1999). One Thai species (Systenostoma edentata) is transferred to the genus Hypselostoma. Vietnamese members remain in the genus Tonkinospira (nomen novum) for Systenostoma Bavay & Dautzenberg, 1908 (non Systenostoma Marsson, 1887). A comprehensive map of former Systenostoma species is presented. SEM and NanoCT images, including a video of A. huoyani sp. n. internal shell morphology, provide novel perspectives of the shells of Angustopila and of the scarcely known Vietnamese Tonkinospira species. The biology of these snails is not yet known but collection localities suggest a troglophilic ecology.
Taxonomy, subterranean snail, Pupillidae, Vertiginidae, conservation, cave-dwelling species
A review of the microgastropod genus Systenostoma Bavay & Dautzenberg, 1908 and a new subterranean species from China (Gastropoda, Pulmonata, Hypselostomatidae)
Adrienne Jochum,1 Rajko Slapnik,2 Marian Kampschulte,3 Gunhild Martels,3 Markus Heneka,4 and Barna Pall-Gergely5
2014;
27908905
Background and objectives
Hepatitis C virus (HCV) infection is widely prevalent among patients on hemodialysis (HD), but very rarely treated. The aim of our study is to evaluate the burdens of HCV suffered by patients on HD.
Design, setting, participants, & measurements
The Dialysis Outcomes and Practice Patterns Study is an international, prospective, cohort study of patients on HD. We reviewed the HCV status of 76,689 adults enrolled between 1996 and 2015. We compared HCV-positive (HCV+) with HCV-negative (HCV−) patients for risk of mortality, hospitalization, decline in hemoglobin concentration <8.5 g/dl, and red blood cell transfusion. We also compared health-related quality of life scores using the Kidney Disease Quality of Life instrument and the Center for Epidemiologic Studies Short Depression Scale. We adjusted for age, sex, race, years on dialysis, 14 comorbid conditions (including hepatitis B infection), and serum albumin, phosphorus, and creatinine concentrations.
Results
A total of 7.5% of patients were HCV+ at enrollment. Serum concentrations of alanine aminotransferase and aspartate aminotransferase were not markedly elevated in HCV+ patients on HD; the mean concentrations were only 22.6 and 21.8 U/L, respectively. Median follow-up was 1.4 years. Case-mix adjusted hazard ratios (95% confidence intervals) for HCV+ versus HCV− patients were 1.12 (1.05 to 1.20) for all-cause mortality, 5.90 (3.67 to 9.50) for hepatic-related mortality, 1.09 (1.04 to 1.13) for all-cause hospitalization, and 4.40 (3.14 to 6.15) for hepatic-related hospitalization. Quality of life measures indicated significantly worse scores for physical function, pain, vitality, mental health, depression, pruritus, and anorexia among HCV+ patients. The adjusted hazard ratio for transfusion was 1.36 (95% CI, 1.20 to 1.55) and incidence of hemoglobin concentration <8.5 g/dl was 1.12 (95% CI, 1.03 to 1.21). Only 1.5% of HCV+ patients received antiviral medication.
Conclusions
HCV infection among patients on HD is associated with higher risk of death, hospitalization, and anemic complications, and worse quality of life scores. Internationally, HCV infection is almost never treated in patients on HD. Our data provide a rationale for more frequent treatment of HCV in this population.
Hepatitis C, mortality, quality of life, anemia, renal dialysis, Adult, Anorexia, Antiviral Agents, creatinine, depression, Epidemiologic Studies, Erythrocyte Transfusion, Follow-Up Studies, Hemoglobins, Hepacivirus, Hepatitis B, hospitalization, Humans, Incidence, Kidney Diseases, Mental, Health, Pain, Phosphorus, Prevalence
Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis
David A. Goodkin, Brian Bieber, Michel Jadoul, Paul Martin, Eiichiro Kanda, Ronald L. Pisoni
2017 Feb 7
27089943
Using next-generation sequencing (NGS) for full genomic characterization studies of the newly emerging avian orthoreovirus (ARV) field strains isolated in Pennsylvania poultry, we identified two co-infection ARV variant strains from one ARV isolate obtained from ARV-affected young layer chickens. The de novo assembly of the ARV reads generated 19 contigs of two different ARV variant strains according to 10 genome segments of each ARV strain. The two variants had the same M2 segment. The complete genomes of each of the two variant strains were 23,493 bp in length, and 10 dsRNA segments ranged from 1192 bp (S4) to 3958 bp (L1), encoding 12 viral proteins. Sequence comparison of nucleotide (nt) and amino acid (aa) sequences of all 10 genome segments revealed 58.1-100% and 51.4-100% aa identity between the two variant strains, and 54.3-89.4% and 49.5-98.1% aa identity between the two variants and classic vaccine strains. Phylogenetic analysis revealed a moderate to significant nt sequence divergence between the two variant and ARV reference strains. These findings have demonstrated the first naturally occurring co-infection of two ARV variants in commercial young layer chickens, providing scientific evidence that multiple ARV strains can be simultaneously present in one host species of chickens.
Detection and characterization of two co-infection variant strains of avian orthoreovirus (ARV) in young layer chickens using next-generation sequencing (NGS)
Yi Tang, Lin Lin, Aswathy Sebastian, Huaguang Lu
2016
Description :
Empty ...
